Anika Top Line Growth Fueled by Parcus and Arthosurface Acquisitions

The company’s 1Q20 growth amid COVID-19 was fueled by $6.8 million in sales from Parcus and Arthosurface, in addition to continuing purchase orders of legacy viscosupplements.

OrthoPediatrics Hits Double-Digit Growth in 1Q20 Despite COVID Downturn

The company rode early 1Q momentum to grow in the low double-digits despite COVID-related procedure deferrals, and has seen signs of incremental recovery in May.

Globus Expects to Emerge from COVID-19 in Stronger Position

The company managed to drive single-digit growth despite the late-March impact of COVID and expects to be well-positioned to benefit from the inevitable market consolidation occurring due to the pandemic.

Smith+Nephew Weekly Sales Decline -47% in April

Orthopedic sales for the company declined 9.5% in 1Q20 before dropping by nearly half through April. However, the company sees initial recovery signs as countries gradually restart elective procedures.

NuVasive in Strong Position to Weather the COVID-19 Storm

NuVasive suffered modest impact from COVID-19 in 1Q20 and expects severe reductions in 2Q. However, the company is using its strong cash position to push forward with product development.

Vericel Confident in Near-Term MACI Recovery

Vericel’s MACI revenue grew 22% in 1Q20 despite mid-March disruptions from COVID-19. The company believes it has passed the market low point and remains confident it will recoup most lost procedures.

COVID-19 Derails SI-BONE’s Record Procedure Trajectory in 1Q20

The company grew in the low double digits in 1Q20 but was on pace for record procedure volumes before COVID-19 impacted the U.S. orthopedic market in mid-March.

Stryker Confident in Orthopedics’ Ability to Bounce Back from COVID-19

While Stryker anticipates significant disruption to orthopedic sales in 2Q20, the company is confident the revenue-generating ability of orthopedics will drive the recovery of deferred procedures.

ConMed Foresees Dramatic Virus-Related Declines in 2Q20

The company declined 12.5% in 1Q20 and believes the market low point will be in the second quarter. ConMed's orthopedic sales for April are projected to decline by 65%.